TY - JOUR
T1 - A phase II trial of amonafide in patients mixed mesodermal tumors of the uterus
T2 - A gynecologic oncology group study
AU - Asbury, Robert
AU - Blessing, John A.
AU - Podczaski, Edward
AU - Ball, Harrison
PY - 1998/6
Y1 - 1998/6
N2 - Amonafide demonstrated a poor response rate and substantial toxicity in patients who had measurable, advanced mixed mesodermal tumors of the uterus. Amonafide-a drug that acts through intercalation of tumor DNA-was used to treat 16 patients who had measurable, advanced mixed mesodermal tumors of the uterus as part of a Gynecologic Oncology Group (GOG) Phase II study. The starting dose was 300 mg/m2 intravenously over 1 hour for 5 consecutive days every 3 weeks. Severe or life-threatening hematologic toxicity occurred in 50% of the patients. Two patients experienced vomiting requiring hospitalization. Other toxicities were not severe. One patient had a partial response and one had stable disease, each lasting 4 months. This dose schedule was associated with poor response rate and substantial toxicity.
AB - Amonafide demonstrated a poor response rate and substantial toxicity in patients who had measurable, advanced mixed mesodermal tumors of the uterus. Amonafide-a drug that acts through intercalation of tumor DNA-was used to treat 16 patients who had measurable, advanced mixed mesodermal tumors of the uterus as part of a Gynecologic Oncology Group (GOG) Phase II study. The starting dose was 300 mg/m2 intravenously over 1 hour for 5 consecutive days every 3 weeks. Severe or life-threatening hematologic toxicity occurred in 50% of the patients. Two patients experienced vomiting requiring hospitalization. Other toxicities were not severe. One patient had a partial response and one had stable disease, each lasting 4 months. This dose schedule was associated with poor response rate and substantial toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0031813475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031813475&partnerID=8YFLogxK
U2 - 10.1097/00000421-199806000-00022
DO - 10.1097/00000421-199806000-00022
M3 - Article
C2 - 9626805
AN - SCOPUS:0031813475
SN - 0277-3732
VL - 21
SP - 306
EP - 307
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 3
ER -
